| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
I successfully established a new computational analysis method named “comparative transcriptome analysis” for the purpose of elucidating a molecular mechanism of “splicing modulators” like TG003 or RECTAS. It is a goal set at the day when this KAKENHI study has been started at 2015. With this method, we found sequence properties shared among TG003-skip-enhanced exons (Sakuma, IIDA, and Hagiwara. 2015), also found that sets of TG003 sensitive exons are clearly different between differentiated and un-differentiated muscle cells. The most importantly, these results suggested that TG003 or RECAS can target exons in nucleotide sequence dependent manners. Based on this finding, I developed a new system for predicting therapeutic potentials of the splicing modulates against personal genome sequences or entries on genome mutation databases. Outcome from the current studies can contribute on improvement of this predicting system.
|
